Japan Results Roundup: Strong Mainstays, Currency Windfall Help Top Line

 
• By Lisa Takagi

Results from the top Japanese pharma firms in the fiscal first quarter were marked mainly by strong global performances for mainstay products and significant currency effects due to the continued weakness of the yen, although forex concerns are rising. Eisai's Alzheimer's drug Leqembi also gained momentum, particularly in the US. 

Major Japanese pharmaceutical firms' Q2 performance was largely supported by their US performance with weak forex rate.
Major Japan pharma firms' Q1 performance supported by global performance, weak yen • Source: Shutterstock

More from Japan

More from Focus On Asia